Targeted therapies: how personal should we go?

  title={Targeted therapies: how personal should we go?},
  author={Miriam Martini and Loredana Vecchione and Salvatore Siena and Sabine Tejpar and Alberto Bardelli},
  journal={Nature Reviews Clinical Oncology},
Despite the development of drugs inhibiting the oncogenic proteins that cancer cells are dependent on, attempts to match targeted therapies to the genetic makeup of individual tumors is proving more difficult than expected. Until now, the paradigm has been a binary correlation between a mutated cancer gene and response to a given therapy. However, recent evidence indicates that different genetic alterations, such as mutations in different codons of a cancer gene, might be related to distinct… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 55 extracted citations

Molecular Applications in Cytology

Springer International Publishing • 2018
View 5 Excerpts
Highly Influenced

Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2018
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 111 references

Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations

Won, W Y.
J. Clin. Pathol • 2011

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer

E Razis
Breast Cancer Res. Treat. 128, • 2011

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy

Morrow, K P.
J. Clin. Oncol • 2011

Similar Papers

Loading similar papers…